Articles

Poll

Podcasts

Slideshows

Videos

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.

SMART-C Meta-Analysis: SGLT2 Inhibitors Reduce Cardiovascular Events

In this episode, hosts discuss the STEP HFpEF DM trial and the need for fair allocation of incretin-based therapies with ongoing shortages and overwhelming demand.

Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies

Ersilia DeFillipis, MD, discusses a trio of studies she presented at ACC.24 examining different financial hurdles and barriers encountered by people in need of heart transplants. 

Ersilia DeFilippis, MD: Need for Equity, Policy Change in Heart Failure Transplant

A retrospective analysis of EHR data from ACC.24 provides insight into the effects of ARNI relative to ACEi/ARB in patients with newly diagnosed heart failure and an LVEF greater than 40%.

Ankeet Bhatt, MD, MBA: Sacubitril/Valsartan vs ACEi/ARB in de novo HFmrEF/HFpEF

Ahmad Masri, MD, MS, discusses a study from ACC.24 examining trends in incidence and outcomes of emergency department visits related to hypertrophic cardiomyopathy from 2006 to 2019.

Understanding Trends in Hypertrophic Cardiomyopathy-Related ED Visits, with Ahmad Masri, MD, MS

Sara Saberi, MD, discusses 1-year data from a cohort of 46 patients within the FOREST-HCM trial at ACC.24.

Sara Saberi, MD: FOREST-HCM Data Demonstrates Long-Term Effects of Aficamten

A trio of experts discuss their perspectives on the recent advancement in pharmacotherapy within the management of hypertrophic cardiomyopathy. 

Experts' Perspectives: Advancements in Cardiomyopathy at ACC.24

Martin Maron, MD, discusses the results of the IMPROVE-HCM trial and how it informs the community on the potential of ninerafaxstat.

Ninerafaxstat Shows Promise in Phase 2 IMPROVE-HCM Trial for Nonobstructive HCM

Veraprapas Kittipibul, MD, discusses an analysis of the TRANSFORM-HF trial at ACC.24.

Modified On-Treatment Analysis Confirms Results of TRANSFORM-HF

Muthiah Vaduganathan, MD, MPH, discusses a presentation from ACC.24 assessing the effects of dapagliflozin across a range of left ventricular hypertrophy from DELIVER.

SGLT2 Inhibition Across a Range of Left Ventricular Hypertrophy, with Muthiah Vaduganathan, MD, MPH

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.